xl092
Small moleculeexperimental
Clinical trial activity
31 trials · 20 clinical orgs · 0 marketing orgs
Phase 1
12
Phase 2
21
Phase 3
5
Phase 4
0
Earliest trial started Feb 26, 2019 (NCT03845166)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 3
- Carcinoma, Squamous Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 2
- Colorectal Neoplasms · Phase 3
- Endometrial Neoplasms · Phase 1
- Fibrosis · Phase 1/Phase 2
- Head and Neck Neoplasms · Phase 1
- Kidney Neoplasms · Phase 2
- Leiomyosarcoma · Phase 2
- Liver Diseases · Phase 1
- Liver Neoplasms · Phase 2
- Mutation · Phase 1
- Neoadjuvant Therapy · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasm Recurrence, Local · Phase 1
- Neoplasms · Phase 2
- Neoplasms, Germ Cell and Embryonal · Phase 1/Phase 2
- Neuroendocrine Tumors · Phase 2
- Osteosarcoma · Phase 2
- Prostatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2/Phase 3
- Thyroid Carcinoma, Anaplastic · Phase 1
- Thyroid Neoplasms · Phase 2
- Uterine Neoplasms · Phase 1
Mechanism of action
MERTK inhibitor
- Tyrosine-protein kinase receptor UFOINHIBITOR
AXL inhibitor
KDR inhibitor
- Hepatocyte growth factor receptorINHIBITOR
MET inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CNC(=O)c1cc2c(Oc3ccc(NC(=O)C4(C(=O)Nc5ccc(F)cc5)CC4)cc3)ccnc2cc1OC- Mol. weight
- 528.54 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314428 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07283731 | Phase 2 | Jun 2, 2026 | Exelixis, University of Texas at Houston |
| NCT07193550 | Phase 2 | May 31, 2026 | Exelixis, University of Texas at Houston |
| NCT07218666 | Phase 2 | May 31, 2026 | Exelixis, Hoosier Cancer Research Network, Medical College of Wisconsin |
| NCT07042919 | Phase 1/Phase 2 (Phase 2) | Mar 4, 2026 | National Cancer Institute (NCI), Northwestern University |
| NCT07226063 | Phase 2 | Feb 28, 2026 | Case Western Reserve University, Exelixis |
| NCT06926634 | Phase 2 | Dec 31, 2025 | Exelixis, Washington University in St. Louis |
| NCT07227402 | Phase 3 | Dec 29, 2025 | Exelixis, Merck |
| NCT07185945 | Phase 2 | Nov 30, 2025 | Advent Health, Exelixis, Hoosier Cancer Research Network |
| NCT06968988 | Phase 1 | Nov 30, 2025 | Exelixis, Washington University in St. Louis |
| NCT06794229 | Phase 2 | Nov 30, 2025 | Exelixis, Hoosier Cancer Research Network, University of Texas, Galveston |
| NCT06937866 | Phase 1/Phase 2 (Phase 2) | Nov 12, 2025 | Exelixis, Indiana University |
| NCT06957431 | Phase 1 | Oct 22, 2025 | Exelixis, Washington University in St. Louis |
| NCT07043608 | Phase 2 | Sep 30, 2025 | Exelixis, University of California, San Francisco |
| NCT06912087 | Phase 1 | Sep 29, 2025 | Exelixis, University of Chicago |
| NCT06959511 | Phase 2 | Jul 22, 2025 | Exelixis, University of Texas at Houston |
| NCT06943755 | Phase 2/Phase 3 (Phase 3) | Jul 21, 2025 | Exelixis |
| NCT07049926 | Phase 1/Phase 2 (Phase 2) | Jul 20, 2025 | Exelixis, Merck |
| NCT06959641 | Phase 2 | Jun 6, 2025 | National Cancer Institute (NCI), Northwestern University |
| NCT06902376 | Phase 1 | Jun 3, 2025 | Exelixis, Regeneron, University of North Carolina at Chapel Hill |
| NCT06795009 | Phase 1 | May 31, 2025 | Exelixis, National Cancer Institute (NCI), Washington University in St. Louis |
Showing 20 of 31 trials
Page 1 / 2
Organizations
Research & Development (20)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Exelixis | For profit | 28 | 8 | 3 | 2019 |
| Hoosier Cancer Research Network | Academic/Hospital | 4 | 4 | 1 | 2025 |
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2024 |
| Washington University in St. Louis | Academic/Hospital | 4 | 4 | 2 | 2025 |
| Northwestern University | Academic/Hospital | 3 | 3 | 1 | 2024 |
| University of Texas at Houston | Academic/Hospital | 3 | 3 | 1 | 2025 |
| Merck | For profit | 2 | 2 | 2 | 2025 |
| Advent Health | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Arcus Biosciences, Inc. | For profit | 1 | 0 | 1 | 2024 |
| Case Western Reserve University | Academic/Hospital | 1 | 1 | 1 | 2026 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Indiana University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Medical College of Wisconsin | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Regeneron | For profit | 1 | 0 | 1 | 2025 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Chicago | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of North Carolina at Chapel Hill | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2024 |
| University of Texas, Galveston | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Utah | Academic/Hospital | 1 | 1 | 1 | 2024 |
20 organizations
Page 1 / 1